How Safe Is Amgen's Dividend?
(NASDAQ: AMGN) has been grabbing headlines lately, and not always for the right reasons. The company is currently engaged in a battle with the U.S. Food and Drug Administration (FDA), which has demanded that the biotech pull Tavneos, a medicine for severe anti-neutrophil cytoplasmic autoantibody-associated vasculitis (a group of rare autoimmune inflammatory diseases), from the market. The FDA is claiming that Amgen manipulated clinical trial data.
Elsewhere, Amgen has been fighting off attempts by Colorado regulators to cap the annual price of its famous psoriatic arthritis drug, Enbrel. Amgen recently won a court victory in that battle, although it probably isn't completely over yet. With all that going on, some might worry about Amgen's business and ability to maintain its dividend program intact. Should investors seek out other dividend stocks?
Image source: The Motley Fool.
Source Fool.com
Amgen Inc. Stock
The stock is one of the favorites of our community with 36 Buy predictions and 2 Sell predictions.
On the other hand, the target price of 332 € is below the current price of 338.75 € for Amgen Inc., so the potential is actually -1.99%.
